Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies

NCT06923761 is registered in ClinicalTrials.gov with Grey Wolf Therapeutics as lead sponsor.

NCT NCT06923761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies
Lead sponsor
Grey Wolf Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 21, 2023
Completion date
April 30, 2028
Enrollment
300 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancy